Washington, DC (UroToday.com) During the Bladder Cancer Award Ceremony, Seth Lerner from Baylor College of Medicine, presented his summary of his 2017 BCAN Innovation Award. He initially discussed the premise of his work in terms of alternative treatment options including immunotherapy, chemotherapy/immunotherapy, and targeted therapy.
The study hypothesis was an integrated analysis of proteomics and genomics of primary muscle-invasive bladder cancer, and patient-derived xenografts will define mechanisms for chemotherapy resistance and identify candidate driver genes leading to the identification of specific targeted therapies for those resistant to the current standard of care. The clinical and banking workflow needed includes post-referral restaging and post-chemotherapy restaging prior to radical cystectomy. This is critical in order to place the tissue in a tumor bank for subsequent analysis. The target for the study is n=80 which has almost finished accrual. Requirements include minimum >50% tumor cellularity, urothelial and variant histology.
Presented by: Seth P. Lerner, MD, FACS, Beth and Dave Swalm Chair in Urologic Oncology, Director of Urologic Oncology, Director of the Multidisciplinary Bladder Cancer Program, Baylor College of Medicine, Houston, Texas
Written by: Stephen B. Williams, MD, Medical Director for High Value Care; Chief of Urology, Associate Professor, Director of Urologic Oncology, Director Urologic Research, The University of Texas Medical Branch at Galveston, TX and Ashish M. Kamat, MD, Professor, Department of Urology, Division of Surgery, The University of Texas MD Anderson Cancer Center, Houston, TX at the 2019 Bladder Cancer Advocacy Network (BCAN) Think Tank August 8-10, 2019 – the Capital Hilton, Washington, DC, USA